Prostate and other male cancers:
Indications for VANTAS:
Palliative treatment of advanced prostate cancer.
Insert 1 implant SC in the inner aspect of the upper arm. Remove after 12 months; may replace.
Initial transient increase in serum testosterone may result in worsening signs/symptoms (eg, bone pain, neuropathy, hematuria). Metastatic vertebral lesions, urinary tract obstruction (monitor closely in 1st few weeks). Avoid wetting inserted arm for 24hrs and heavy lifting or strenuous exertion for 1st week. Increased risk of developing diabetes; monitor blood glucose and HbA1c periodically; treat if occurs. Increased risk of developing MI, sudden cardiac death, stroke; monitor for signs/symptoms of cardiovascular disease. May prolong QT/QTc interval in patients with congenital long QT syndrome, CHF, electrolyte abnormalities (correct and monitor); monitor ECGs. Measure serum testosterone, PSA levels periodically. Implant not visible on X-ray. Embryo-fetal toxicity. Pregnancy. Nursing mothers.
May interfere with pituitary gonadotropic and gonadal function tests. Caution with concomitant drugs known to prolong the QT interval.
Hot flashes, fatigue, implant site reactions, testicular atrophy; hyperglycemia, diabetes, cardiovascular disease.
Kit—1 (w. implant and supplies)